Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests

Treatment with the experimental gold nanocrystal therapy CNM-Au8 decreased the risk of mortality by 64% among people with early amyotrophic lateral sclerosis (ALS), compared to what would be expected without treatment, according to new analyses from the RESCUE-ALS clinical trial. The findings were presented by Clene Nanomedicine,…

Lead Antibody Targeting Toxic TDP-43 Protein to Advance, ProMIS Says

ProMIS Neurosciences announced plans to advance a monoclonal antibody against toxic TDP-43 protein clumps as a potential treatment for amyotrophic lateral sclerosis (ALS). The candidate antibody therapy, called PMN267, has shown promise in preclinical experiments conducted at independent institutions, the company also reported in a press release. Nearly all cases…

AMX0035 Extended Patients’ Survival By More Than 10 Months

Treatment with AMX0035 significantly extended the median survival of amyotrophic lateral sclerosis (ALS) patients by more than 10 months compared with a placebo, a new analysis of the Phase 2/3 CENTAUR clinical trial indicates. That survival difference was even greater in patients who continued to receive AMX0035 in the open-label…

Wave Life’s WVE-004 Shows Proof of Concept in Cell, Mouse Models

WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, has demonstrated proof-of-concept efficacy in cell and animal models, a new study shows. The nucleic acid-based therapy was able to “potently” reduce the toxic RNA molecules and small proteins…

WVE-004 Reduces Toxic Proteins, Early FOCUS-C9 Data Suggests

The experimental therapy WVE-004 appears to be engaging its intended target and reducing the amount of toxic proteins in people with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) caused by mutations in the C9orf72 gene, according to early data from the FOCUS-C9 clinical trial. The trial is currently recruiting adults,…